Compare eBay Inc (EBAY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs TG Therapeutics Inc — how do they compare? eBay Inc trades at $112.19 (market cap $49.83B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: eBay Inc is far larger — about 6.1× TG Therapeutics Inc's market cap, and eBay Inc pays a 1.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold eBay Inc for 134 Days and TG Therapeutics Inc for 16 Days on average.
| EBAY | TGTX | |
|---|---|---|
Market Cap | $49.83B | $8.16B |
Volume | 2,986,953 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $59.06 |
52-Week Low | $79.41 | $26.94 |
Typical Hold Time | 134 Days | 16 Days |
Enterprise Value | $53.65B | $8.37B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $111.98, up 4.07% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains robust profitability with 72.05% gross margins and 18.57% net income margin, supported by $11.1B in revenue. Technical indicators show bullish momentum with the current price near resistance at $113, while analyst consensus remains positive with a $117.68 price target. Recent news highlights eBay's focus on collectibles and live commerce growth initiatives.
EBAY presents a balanced investment case with strong fundamentals and positive earnings momentum offset by competitive pressures. The 4% upside to consensus target and consistent profitability support bullish sentiment, though investor caution is warranted given recent insider selling and potential acquisition-related volatility from GameStop's stake. Revenue growth acceleration to $12B in 2026 provides fundamental support for continued appreciation.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
